Accelerating Oncology Naviguard Prior Authorizations with Klivira

Klivira automates the intricate prior authorization process for oncology Naviguard submissions, ensuring timely access to critical cancer treatments and reducing administrative burden.

For revenue cycle directors and prior authorization coordinators in cancer care, managing utilization management for high-cost oncology treatments is exceptionally complex. The unique cadence of cancer therapy, involving frequent regimen changes and a mix of medical and pharmacy benefit drugs, makes efficient processing of oncology Naviguard requests crucial for patient access and financial health.

The Unique Demands of Oncology Prior Authorization

Oncology prior authorization is characterized by its high volume and complexity, driven by high-cost biologics, advanced imaging, and dynamic treatment regimens. Each patient often requires numerous PA events across diagnosis, treatment initiation, and ongoing surveillance, making efficient management critical for patient outcomes and operational efficiency.

Key Prior Authorization Triggers in Oncology for Naviguard

HCPCS J-codes for chemotherapy, biologics, and immunotherapies
Advanced imaging for staging and surveillance (PET/CT, advanced MRI)
Radiation oncology procedures (IMRT, IGRT, SBRT, proton-beam therapy)
Genetic and molecular testing for treatment selection
Supportive care medications (e.g., G-CSF, ESAs)

Naviguard's Role in Oncology Utilization Management

As a utilization management program under UnitedHealthcare, Naviguard plays a significant role in reviewing oncology treatment plans. Given the high cost and specialized nature of cancer care, Naviguard's review process often requires detailed clinical documentation aligned with established guidelines like the NCCN Clinical Practice Guidelines.

Essential Documentation for Oncology Naviguard Submissions

Pathology reports confirming diagnosis and tumor staging (AJCC TNM)
Molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1) relevant to treatment selection
Documentation of prior-line treatments, response, and rationale for regimen changes
Performance status (ECOG or Karnofsky score) supporting fitness for therapy
NCCN Drugs & Biologics Compendium citation for off-label drug use

Klivira's Approach to Streamlining Oncology Naviguard PAs

Klivira's automation platform is engineered to navigate the specific complexities of oncology prior authorizations, including those managed by Naviguard. By integrating directly with EMRs and payer portals, Klivira reduces manual effort, accelerates submission times, and enhances compliance with payer-specific requirements, such as those informed by NCCN guidelines.

Klivira Capabilities for Oncology Naviguard Workflows

NCCN-compendium-aware policy logic guiding documentation requirements
Regimen-level PA workflow for bundling related treatment components
Automated routing for medical-benefit (X12 278) and pharmacy-benefit (ePA via NCPDP SCRIPT) drug PAs
Concurrent tracking of multiple PA events per patient across their treatment course
Integration for efficient peer-to-peer review scheduling

Frequently asked questions

How does Klivira address the "start-of-treatment urgency" common in oncology when dealing with Naviguard PAs?

Klivira's platform accelerates PA submission by automating data extraction from EMRs and pre-populating forms, significantly reducing manual steps. This efficiency helps minimize delays in securing Naviguard approvals, allowing for quicker treatment initiation for urgent oncology cases.

What specific oncology PA denial reasons, often seen with Naviguard, does Klivira help mitigate?

Klivira helps mitigate denials related to documentation gaps by prompting for all required clinical details, including molecular markers and NCCN Compendium citations. It also supports appeals for off-label use and step therapy denials by ensuring comprehensive submission of supporting evidence.

Can Klivira handle both medical and pharmacy benefit prior authorizations for oncology drugs reviewed by Naviguard?

Yes, Klivira's platform is designed to manage the split benefit landscape of oncology. It intelligently routes medical-benefit PA requests through appropriate channels (e.g., X12 278) and pharmacy-benefit ePA requests via PBM partners, ensuring all Naviguard submissions follow the correct pathway.

How does Klivira support the frequent regimen changes and multiple PA events typical for an oncology patient?

Klivira provides concurrent PA tracking, allowing clinics to manage dozens of PA events per patient throughout their treatment journey. This includes new regimen PAs, supportive care PAs, and surveillance imaging PAs, offering a consolidated view and automated follow-ups for all Naviguard-related requests.